Metastatic breast cancer with liver metastases: A registry analysis of clinicopathologic, management and outcome characteristics of 500 women

Breast Cancer Research and Treatment

Volumn 97, Issue 3, 2006, Pages 237-244

  Pentheroudakis, George ^a,b   Fountzilas, George ^a   Bafaloukos, Dimitrios ^a   Koutsoukou, Vasiliki ^a   Pectasides, Dimitrios ^a   Skarlos, Dimosthenis ^a   Samantas, Epaminondas ^a   Kalofonos, Haralabos P ^a   Gogas, Helen ^a   Pavlidis, Nicholas ^a  

^a Hellenic Cooperative Oncology Group   (Greece)

^b UNIVERSITY HOSPITAL OF IOANNINA   (Greece)

Author keywords

Breast cancer; Chemotherapy; Liver metastases; Prognostic factors; Survival

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; CAPECITABINE; CARBOPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; GEMCITABINE; HORMONE RECEPTOR; METHOTREXATE; NAVELBINE; PACLITAXEL; PROGESTERONE RECEPTOR; TAXANE DERIVATIVE;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER PALLIATIVE THERAPY; CANCER REGRESSION; CANCER RELAPSE; CANCER SURVIVAL; COHORT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DISEASE COURSE; EARLY DIAGNOSIS; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LIVER METASTASIS; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PATIENT MONITORING; POSTMENOPAUSE; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; TUMOR VOLUME;

ADULT; AGED; ANTHRACYCLINES; ANTIBIOTICS, ANTINEOPLASTIC; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BREAST NEOPLASMS; FEMALE; GREECE; HUMANS; LIVER NEOPLASMS; MIDDLE AGED; PROGNOSIS; REGISTRIES; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TAXOIDS; TREATMENT OUTCOME;

EID: 33745360907     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10549-005-9117-4     Document Type: Article

References (12)

1. Zinser JW, Hortobagyi GN, Buzdar AU, Smith TL, Fraschini G: Clinical course of breast cancer patients with liver metastases. J Clin Oncol 5: 773-782, 1987
2. O'Reilly SM, Richards MA, Rubens RD: Liver metastases from breast cancer: the relationship between clinical, biochemical and pathological features and survival. Eur J Cancer 26: 574-577, 1990
3. Hoe AL, Royle GT, Taylor I: Breast liver metastases-incidence, diagnosis and outcome. J R Soc Med 84: 714-716, 1991
4. Fumoleau P: Treatment of patients with liver metastases. Anticancer Drugs 7(Suppl 2): 21-23, 1996
5. Paridaens R, Biganzoli L, Bruning P et al.: Paclitaxel versus doxorubicin as first-line single-agent chemotherapy for metastatic breast cancer: a EORTC randomized study with cross-over. J Clin Oncol 18: 724-733, 2000
6. Biganzoli L, Cufer T, Bruning P et al.: Doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first-line chemotherapy in metastatic breast cancer: the EORTC 10961 multicenter phase III trial. J Clin Oncol 20: 3114-3121, 2002
7. Chan S, Friedrichs K, Noel D et al.: Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. The 303 Study Group. J Clin Oncol 17: 2341-2354, 1999
8. Miller KD, Wang M, Gralow J et al.: E2100: a randomized phase III trial of paclitaxel versus paclitaxel plus bevacizumab as first-line therapy for locally recurrent or metastatic breast cancer. Proc Am Soc Clin Oncol late-breaking abstr., 2005
9. Kelly K: The benefits of achieving stable disease in advanced lung cancer. Oncology 17: 957-963, 2003
10. Nabholtz JM, Reese DM, Lindsay MA, Riva A: Docetaxel in the treatment of breast cancer: an update on recent studies. Semin Oncol 29(Suppl 12): 28-34, 2002
11. Castiglione-Gertsch M, Johnsen C, Goldhirsch A: The International (Ludwig) Breast Cancer Study Group Trials I-IV: 15 years follow up. Ann Oncol 5: 717-724, 1994
12. Atalay G, Biganzoli L, Renard F, Paridaens R, Cufer T et al.: Clinical outcome of breast cancer patients with liver metastases alone in the anthracycline-taxane era: a retrospective analysis of two prospective, randomized metastatic breast cancer trials. Eur J Cancer 39: 2439-2449, 2003